Department of Internal Medicine I, Friedrich Schiller University, Jena, Germany.
Can J Cardiol. 2011 May-Jun;27(3):363-8. doi: 10.1016/j.cjca.2010.12.066. Epub 2011 Apr 19.
Cardiac resynchronization therapy (CRT) is an established treatment of severe systolic heart failure with intraventricular conduction delay. The influence on mortality of the left ventricular (LV) pacing site and the type of bundle-branch block during CRT is unclear.
This study investigates the clinical significance of LV lead position, as well as nonspecific conduction delay, in CRT.
143 consecutive patients (mean age, 63.9 ± 8.9 years; 121 men) underwent implantation of a CRT device according to established criteria. At the time of implantation, the LV lead position and the type of bundle-branch block were recorded. The etiology of the heart failure was ischemic in 49 patients (34.3%) and nonischemic in 94 patients (65.7%).
After a median follow-up of 19 months, 39 patients (27.3%) died, most of them (72%) of cardiovascular causes. The mortality was significantly higher in patients with an anterior or anterolateral LV lead position (P = 0.03). Multivariate analysis suggests that an anterior or anterolateral LV lead position, a nonspecific conduction delay, male sex, and a New York Heart Association functional class worse than III, are all independent predictors of mortality during the follow-up period.
LV lead position and nonspecific conduction delay are predictors of mortality in patients during cardiac resynchronization therapy.
心脏再同步治疗(CRT)是治疗严重收缩性心力衰竭伴室内传导延迟的一种既定方法。左心室(LV)起搏部位和 CRT 期间束支传导阻滞的类型对死亡率的影响尚不清楚。
本研究探讨 LV 导联位置以及 CRT 中无特异性传导延迟的临床意义。
143 例连续患者(平均年龄 63.9±8.9 岁;男性 121 例)根据既定标准植入 CRT 设备。在植入时,记录 LV 导联位置和束支传导阻滞的类型。心力衰竭的病因在 49 例患者(34.3%)中为缺血性,在 94 例患者(65.7%)中为非缺血性。
在中位随访 19 个月后,39 例患者(27.3%)死亡,其中大多数(72%)死于心血管原因。LV 导联位于前或前外侧的患者死亡率明显更高(P=0.03)。多变量分析表明,LV 导联位于前或前外侧、无特异性传导延迟、男性和纽约心脏协会功能分级差于 III 级,都是随访期间死亡率的独立预测因素。
LV 导联位置和无特异性传导延迟是 CRT 期间患者死亡率的预测因素。